Nwam LLC Seagen Inc. Transaction History

Nwam LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$187.64 - $206.25 $141,480 - $155,512	-754 Reduced 9.94%	6,829 $1.31 Million
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $255 - $406	-2 Reduced 0.03%	7,583 $1.54 Million
Q4 2022 Feb 07, 2023	SELL	$117.37 - $139.17 $9,624 - $11,411	-82 Reduced 1.07%	7,585 $974,000
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $45,585 - $60,697	337 Added 4.6%	7,667 $1.05 Million
Q2 2022 Aug 10, 2022	BUY	$108.81 - $179.33 $217 - $358	2 Added 0.03%	7,330 $1.3 Million

Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $5,980 - $7,892	-50 Reduced 0.68%	7,328 $1.06 Million
Q4 2021 Feb 10, 2022	BUY	$142.57 - $190.86 $677,777 - $907,348	4,754 Added 181.17%	7,378 $1.14 Million
Q3 2021 Nov 03, 2021	BUY	$142.45 - $169.82 $373,788 - $445,607	2,624 New	2,624 $446,000
Q1 2021 Apr 23, 2021	SELL	$137.51 - $190.8 $225,378 - $312,721	-1,639 Closed	0 $0
Q4 2020 Jan 22, 2021	BUY	$164.63 - $211.93 $269,828 - $347,353	1,639 New	1,639 $287,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

Stay updated on Nwam LLC with notifications on news.